Brief: Walmer Capital says transaction with Renex terminated
01/02/2016 11:30
Feb 1 (Reuters) - Walmer Capital Corp WALh.V : * Provides corporate update * Says actively pursuing two alternative possibilities for qualifying transactions and will report further on their progress * Transaction with renex terminated due to the inability of Walmer to complete a minimum financing for gross proceeds of at least $1 million * Says shares remain suspended from trading and it is expected that trading will remain suspended until completion of a qualifying transaction * Source text for Eikon ID:nCCN9LV8jf * Further company coverage WALh.V ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Nurexone Biologic
See all newsBrief: Nurexone Announces Binding MoU With Made Scientific For U.S. Gmp Manufacturing And Commercial Supply Partnership
Brief: Corporate Updates – Nurexone Appoints Mr. David Stolick To The Board Of Directors
Brief: Exo-Top, Nurexone’S Wholly Owned U.S. Subsidiary, Enters Into Binding MoU For Naïve Exosome Distribution In Mexico
Brief: Nurexone Biologic’S U.S. Subsidiary Exo-Top And Florida-Based Bioxtek Sign Strategic Loi For Exosome Manufacturing And Commercialization
Brief: Nurexone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement